- Ideas
- Markets
- Cryptocurrencies
- Currencies
- Stocks
- Earnings Calendar
- Stock Screener
- Large-Cap
- Top Gainers
- Top Losers
- Most Active
- Most Volatile
- Overbought
- Oversold
- All Time High
- All Time Low
- Sector & Industry
Apple, Advanced Micro Devices Inc, Amazon Com Inc, TESLA INC, NETFLIX INC, Facebook Inc
- Indices
S&P 500, Nasdaq Composite, Dow 30, Nikkei 225, DAX Index, FTSE 100
- Futures
- Bonds
US 10Y, Euro Bund, Germany 10Y, Japan 10Y Yield, UK 10Y, India 10Y
- CFDs
Gold, Brent Oil, Crude Oil, CFDs on Natural Gas, Palladium, Silver
- Scripts
- Oscillators
- Centered Oscillators
- Volatility
- Trend Analysis
- Volume
- Moving Average
- Exponential Moving Average (EMA)
- Weighted Moving Average (WMA)
- Simple Moving Average (SMA)
- Hull Moving Average (HMA)
- Kaufman's Adaptive Moving Average (KAMA)
- Smoothed Moving Average (SMMA)
- Variable Index Dynamic Average (VIDYA)
- Volume-weighted Moving Average (VWMA)
- Fractal Adaptive Moving Average (FRAMA)
- Double Exponential Moving Average (DEMA)
- Breadth Indicators
- Bill Williams Indicators
- Screener
- Shows
- Chart
- More
CORTEXYME INC
NASDAQ
CRTX
CRTX
CORTEXYME INC
Next Earning
Market Cap
EPS
Div Yield
P/E
Next Earning
Market Cap
EPS
Div Yield
P/E
CRTX, 120
Long
Please bear with me (or bull with me in a year) as I am new to this. I am new to investing and have been following biotech IPOs recently. I am just starting to learn technical analysis so I will have to update this later when there is more data to analyze and when I learn how to do that. Also disclaimer: I have an MD background but do not have any stake in this...
2
Valuation
Enterprise Value/EBITDA, TTM
—
Enterprise Value, FQ
—
Market Cap — Basic
—
Number of Employees
—
Number of Shareholders
—
Price/Earnings, TTM
—
Price/Revenue, TTM
—
Price/Book Ratio, FY
—
Price/Sales Ratio, FY
—
Balance Sheet
Current Ratio, FQ
—
Debt to Equity, FQ
—
Net Debt, FQ
—
Quick Ratio, FQ
—
Total Assets, FQ
—
Total Debt, FQ
—
Operating Metrics
Return on Assets, TTM
—
Return on Equity, TTM
—
Return on Invested Capital, TTM
—
Revenue per Employee, TTM
—
Price History
Average Volume (10 day)
—
Beta - 1 Year
—
Price - 52 Week High
—
Price - 52 Week Low
—
Dividends
Dividends Paid, FY
—
Dividends per Share, FY
—
Expected Annual Dividends
—
Dividends Yield
—
Margins
Net Margin, TTM
—
Gross Margin, TTM
—
Operating Margin, TTM
—
Pretax Margin, TTM
—
Income Statement
Basic EPS, Net Income
—
Earnings per Share, Basic, TTM
—
EBITDA, TTM
—
Gross Profit, FY
—
Last Annual EPS
—
Last Annual Revenue, FY
—
Net Income, FY
—
Total Revenue, FY
—
Free Cash Flow, TTM
—
Sector: Healthcare
Industry: Biotechnology & Medical Research
Employees: 19
Cortexyme, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on providing disease-modifying therapeutics to treat Alzheimer’s and other degenerative diseases. The Company is focused on a infectious pathogen tied to neurodegeneration in humans and animal models. The Company’s lead drug candidate, COR388, is an orally-administered, brain-penetrating small molecule gingipain inhibitor designed for the treatment of Alzheimer’s disease. COR388 is designed to target an upstream driver of multiple Alzheimer’s pathological pathways, including amyloid beta production, inflammation and neurodegeneration, in contrast to mechanisms of action targeting downstream effects, such as amyloid plaques and tau tangles.
News
Community & Tools
For Business
© 2019 TradingView
Stock Charts & Forex Charts
Stock Charts & Forex Charts
Made with
From the creators of MultiCharts
Select market data provided by ICE Data Services